A Safety Study of sNN0029 Administration Via Intracerebroventricular Route to Patients With ALS

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
This is a phase I, multicentre randomised, double-blind, placebo-controlled trial to assess the safety and tolerability of continuous i.c.v. administration of sNN0029 infusion solution at a dose of 4µg/day in patients with Amyotrophic Lateral Sclerosis (ALS).
Epistemonikos ID: 34fefd4b7cfb772bee01670d97ba546a39052661
First added on: May 11, 2024